Xi'an Key Laboratory of Stem Cell and Regenerative Medicine, Institute of Medical Research, Northwestern Polytechnical University, Xi'an, Shaanxi 710072, China.
Department of Urology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710032, China.
Theranostics. 2024 Jan 1;14(1):379-391. doi: 10.7150/thno.89495. eCollection 2024.
Endosialin, also known as tumor endothelial marker 1 (TEM1) or CD248, is a single transmembrane glycoprotein with a C-type lectin-like domain. Endosialin is mainly expressed in the stroma, especially in cancer-associated fibroblasts and pericytes, in most solid tumors. Endosialin is also expressed in tumor cells of most sarcomas. Endosialin can promote tumor progression through different mechanisms, such as promoting tumor cell proliferation, adhesion and migration, stimulating tumor angiogenesis, and inducing an immunosuppressive tumor microenvironment. Thus, it is considered an ideal target for cancer treatment. Several endosialin-targeted antibodies and therapeutic strategies have been developed and have shown preliminary antitumor effects. Here, we reviewed the endosialin expression pattern in different cancer types, discussed the mechanisms by which endosialin promotes tumor progression, and summarized current therapeutic strategies targeting endosialin.
内皮细胞唾液酸糖蛋白(endosialin)，又称为肿瘤内皮标志物 1（TEM1）或 CD248，是一种具有 C 型凝集素样结构域的单一跨膜糖蛋白。内皮细胞唾液酸糖蛋白主要表达于基质中，尤其是在大多数实体瘤的癌相关成纤维细胞和周细胞中。内皮细胞唾液酸糖蛋白也表达于大多数肉瘤的肿瘤细胞中。内皮细胞唾液酸糖蛋白可通过不同机制促进肿瘤进展，如促进肿瘤细胞增殖、黏附与迁移，刺激肿瘤血管生成，并诱导免疫抑制性肿瘤微环境。因此，它被认为是癌症治疗的理想靶点。目前已经开发出了几种针对内皮细胞唾液酸糖蛋白的抗体和治疗策略，并显示出初步的抗肿瘤作用。本文综述了内皮细胞唾液酸糖蛋白在不同癌症类型中的表达模式，讨论了内皮细胞唾液酸糖蛋白促进肿瘤进展的机制，并总结了目前针对内皮细胞唾液酸糖蛋白的治疗策略。
